Top Industry Leaders in the Contrast Media Market
GE Healthcare (US) Received FDA approval for its OptiMARK™ (gadoversetic acid) injection in September 2023, expanding its contrast media portfolio for hepatobiliary and neurologic MRI examinations.
Bracco Diagnostics Launched its ProHance® Hydrated (iodixanol injection) in June 2023, offering a low-osmolarity contrast agent with extended imaging window for both CT and MRI procedures.
Guerbet (France) Partnered with Yiming Pharmaceutical Technologies, Ltd. (China) in August 2023 to commercialize its Dotarem® (gadobutrol) contrast agent in China, expanding its global reach.
Bayer AG (Germany) Announced plans to invest €40 million in its Italian manufacturing facility for contrast media in July 2023, showcasing continued commitment to production and market expansion.
Lantheus Medical Imaging Received FDA approval for its Lumify™ (iobenguane I-123) injection in October 2023, a novel radiopharmaceutical for the detection of suspected pheochromocytoma and paraganglioma tumors.
List of Contrast Media Key Companies in the Market
- Bayer AG (Germany)
- Bracco Diagnostic Inc (U.S.)
- DAIICHI (Japan)
- NANOSCAN IMAGING (US)
- Jodas Expoim (India)
- E. Healthcare (U.S.)
- Guerbet Group (France)
- Lantheus Medical Imaging Inc (U.S.)
- Taejoon Pharm (Korea)
- Magnus Health (U.S.)